Every AI express, investors ask questions on the investor interaction platform: on the basis of Xiaoer Feire Kechuan oral liquid, Xiaoer Qingre Zhike granule, Qiangli loquat dew and Angong Niuhuang Pill, Sunflower Pharmaceutical Group Co.Ltd(002737) (002737) varieties are added: Qingre Jiedu oral liquid and Xiaoer Kechuanling oral liquid. Does the company develop drugs for children infected with covid-19 pneumonia? Or can the company’s drugs assist in the treatment of children with mild covid-19 pneumonia? At present, children infected with covid-19 pneumonia has increased. It is recommended that the company continue to pay attention to children’s medication and innovation.
Sunflower Pharmaceutical Group Co.Ltd(002737) (002737. SZ) said on the investor interaction platform on January 14 that the company’s product children’s Feire Kechuan oral liquid was recommended to treat children’s covid-19. In the future, the company will also adhere to the R & D strategy of “purchase, reform, association, research and generation” and continue to strengthen the development of children’s drugs.
